Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy

• Conditions: Head and Neck Cancers Patients

• Registration Number: NCT03325036
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05-01
• Status Verified: 2017-07
• Study First Submitted: 2017-10-24
• Study First Submitted QC: 2017-10-25
• Last Update Submitted: 2017-10-25
• Study First Posted: 2017-10-30
• Last Update Posted: 2017-10-30
• Primary Completion: 2018-12-30
• Study Completion: 2018-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department.

Exclusion Criteria

• Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease progression	Three years	Tumor local recurrence or distant metastasis

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan